Coronary artery bypass surgery (CABG)

Can A Computer Tell Patients How Their Multiple Sclerosis Will Progress?

Method of Research

Computational simulation/modeling

Article Title

Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

COI Statement

Competing Interests: The authors declare no competing non-financial interests but the following competing financial interests: - Dana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva, Roche, Sanofi Genzyme, and Novartis, as well as support for research activities from Biogen and Czech Minsitry of Education [project Progres Q27/LF1]. - Francesco Patti received speaker honoraria and advisory board fees from Almirall, Bayer, Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and TEVA. He received research funding from Biogen, Merck, FISM (Fondazione Italiana Sclerosi Multipla), Reload Onlus Association and University of Catania. - Guillermo Izquierdo received speaking honoraria from Biogen, Novartis, Sanofi, Merck, Roche, Almirall and Teva. - Sara Eichau received speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche and Teva. - Marc Girard received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD. He has also received a research grant from Canadian Institutes of Health Research. - Alessandra Lugaresi has served as a Biogen, Bristol Myers Squibb, Merck Serono, Novartis, Roche, Sanofi/ Genzyme and Teva Advisory Board Member. She received congress and travel/accommodation expense compensations or speaker honoraria from Biogen, Merck, Mylan, Novartis, Roche, Sanofi/Genzyme, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institutions received research grants from Novartis and Sanofi Genzyme. - Pierre Grammond has served in advisory boards for Novartis, EMD Serono, Roche, Biogen idec, Sanofi Genzyme, Pendopharm and has received grant support from Genzyme and Roche, has received research grants for his institution from Biogen idec, Sanofi Genzyme, EMD Serono. - Tomas Kalincik served on scientific advisory boards for BMS, Roche, Janssen, Sanofi Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Eisai, Novartis, Biogen, Sanofi-Genzyme, Teva, BioCSL and Merck and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene and Merck. - Raed Alroughani received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche and Sanofi-Genzyme. - Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals. - Murat Terzi received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis. - Jeannette Lechner-Scott travel compensation from Novartis, Biogen, Roche and Merck. Her institution receives the honoraria for talks and advisory board commitment as well as research grants from Biogen, Merck, Roche, TEVA and Novartis. - Samia J. Khoury received compensation for participation in the Novartis Maestro program. - Vincent van Pesch has received travel grants from Merck, Biogen, Sanofi, Bristol Myers Squibb, Almirall and Roche; his institution receives honoraria for consultancy and lectures and research grants from Roche, Biogen, Sanofi, Merck, Bristol Myers Squibb, Janssen, Almirall and Novartis Pharma. - Radek Ampapa received conference travel support from Novartis, Teva, Biogen, Bayer and Merck and has participated in a clinical trials by Biogen, Novartis, Teva and Actelion. - Daniele Spitaleri received honoraria as a consultant on scientific advisory boards by Bayer-Schering, Novartis and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva and Merck. - Claudio Solaro served on scientific advisory boards for Merck, Genzyme, Almirall, and Biogen; received honoraria and travel grants from Sanofi Aventis, Novartis, Biogen, Merck, Genzyme and Teva. - Davide Maimone served on scientific advisory boards for Bayer, Biogen, Merck, Sanofi-Genzyme, Novartis, Roche, and Almirall; received honoraria and travel grants from Sanofi Genzyme, Novartis, Biogen, Merck, and Roche. - Gerardo Iuliano (retired - no PI successor but has approved ongoing use of data) had travel/accommodations/meeting expenses funded by Bayer Schering, Biogen, Merck, Novartis, Sanofi Aventis, and Teva. - Bart Van Wijmeersch received research and travel grants, honoraria for MS-Expert advisor and Speaker fees from Bayer-Schering, Biogen, Sanofi Genzyme, Merck, Novartis, Roche and Teva. - Tamara Castillo Triviño received speaking/consulting fees and/or travel funding from Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. - Jose Luis Sanchez-Menoyo accepted travel compensation from Novartis, Merck and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer and Teva and has participated in clinical trials by Biogen, Merck and Roche - Guy Laureys received travel and/or consultancy compensation from Sanofi-Genzyme, Roche, Teva, Merck, Novartis, Celgene, Biogen. - Anneke van der Walt served on advisory boards and receives unrestricted research grants from Novartis, Biogen, Merck and Roche She has received speaker's honoraria and travel support from Novartis, Roche, and Merck. She receives grant support from the National Health and Medical Research Council of Australia and MS Research Australia. - Jiwon Oh has received research funding from the MS Society of Canada, National MS Society, Brain Canada, Biogen, Roche, EMD Serono (an affiliate of Merck KGaA); and personal compensation for consulting or speaking from Alexion, Biogen, Celgene (BMS), EMD Serono (an affiliate of Merck KGaA), Novartis, Roche, and Sanofi-Genzyme. - Ayse Altintas received speaker honoraria from Merck, Alexion,; received travel and registration grants from Merck, Biogen - Gen Pharma, Roche, Sanofi-Genzyme. - Yara Fragoso received honoraria as a consultant on scientific advisory boards by Novartis, Teva, Roche and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva, Roche and Merck. - Tunde Csepany received speaker honoraria/ conference travel support from Bayer Schering, Biogen, Merck, Novartis, Roche, Sanofi-Aventis and Teva. - Suzanne Hodgkinson received honoraria and consulting fees from Novartis, Bayer Schering and Sanofi, and travel grants from Novartis, Biogen Idec and Bayer Schering. - Norma Deri received funding from Bayer, Merck, Biogen, Genzyme and Novartis. - Bruce Taylor received funding for travel and speaker honoraria from Bayer Schering Pharma, CSL Australia, Biogen and Novartis, and has served on advisory boards for Biogen, Novartis, Roche and CSL Australia. - Fraser Moore participated in clinical trials sponsored by EMD Serono and Novartis. - Orla Gray received honoraria as consultant on scientific advisory boards for Genzyme, Biogen, Merck, Roche and Novartis; has received travel grants from Biogen, Merck, Roche and Novartis; has participated in clinical trials by Biogen and Merck. - Csilla Rozsa received speaker honoraria from Bayer Schering, Novartis and Biogen, congress and travel expense compensations from Biogen, Teva, Merck and Bayer Schering. - Allan Kermode received speaker honoraria and scientific advisory board fees from Bayer, BioCSL, Biogen, Genzyme, Innate Immunotherapeutics, Merck, Novartis, Sanofi, Sanofi-Aventis, and Teva. - Magdolna Simo received speaker honoraria from Novartis, Biogen, Bayer Schering; congress/travel compensation from Teva, Biogen, Merck, Bayer Schering. - Todd Hardy has received speaking fees or received honoraria for serving on advisory boards for Biogen, Merck, Teva, Novartis, Roche, Bristol-Myers Squibb and Sanofi-Genzyme, is Co-Editor of Advances in Clinical Neurosciences and Rehabilitation, and serves on the editorial board of Journal of Neuroimmunology and Frontiers in Neurology. - Nikolaos Grigoriadis received honoraria, consultancy/lecture fees, travel support and research grants from Biogen Idec, Biologix, Novartis, TEVA, Bayer, Merck Serono, Genesis Pharma, Sanofi – Genzyme, ROCHE, Cellgene, ELPEN and research grants from Hellenic Ministry of Development.

BMS Gains EMA Validation For Opdivo/Yervoy Combo In Liver Cancer

Bristol Myers Squibb has announced that the European Medicines Agency (EMA) will begin a review of its application covering the Opdivo (nivolumab)/Yervoy (ipilimumab) combination's use in patients with advanced liver cancer.

As per the 19 July press announcement, the Type II variation application covers the combination medicine's use as a first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma (HCC) who have not previously undergone systemic therapy. The application is supported by data from the Phase III CheckMate-9DW study (NCT04039607).

Last month, BMS presented CheckMate-9DW clinical data at the 2024 American Society of Clinical Oncology (ASCO) Congress. In the study, treatment with the Opdivo/Yervoy combination resulted in a median overall survival (OS) benefit of 3.1 months over first-line oral multikinase inhibitors (TKIs)—exhibiting an OS of 23.7 months versus 20.6 months. The median follow-up duration was 35.2 months. The overall response rate (ORR) was 36%, and the combination demonstrated an OS rate of 49% and 38% at 24 and 36 months, respectively.

According to GlobalData Healthcare analysts, while positive data bolsters the chances of BMS's combination therapy being used as a first-line HCC therapy, early OS data, and elements of the exclusion criteria make it difficult to determine if the treatment would be preferred by physicians. However, analysts commented that the trial design was "a step up" compared to those adopted by competitors in this space because BMS chose comparator drugs like Eisai's Lenvima (lenvatinib) and Bayer's Nexavar (sorafenib), which reflect a "more contemporary" standard of care.

Opdivo, a programmed death-1 (PD-1) immune checkpoint inhibitor, is approved to treat a variety of cancers, including renal cell carcinoma, gastric cancer, B cell Hodgkin lymphoma and urothelial carcinoma. Yervoy, a cytotoxic T-lymphocyte associated protein 4 (CTLA-4)-inhibiting monoclonal antibody, is approved as a monotherapy for the treatment of unresectable or metastatic melanoma. The Opdivo/Yervoy combination has been approved for several oncology indications such as renal cell carcinoma, metastatic colorectal cancer, and malignant mesothelioma. Still, the combination treatment missed the mark recently in a Phase III non-small cell lung cancer (NSCLC) study (NCT04026412).

According to GlobalData's consensus forecasts, Opdivo is anticipated to generate total sales of $13bn in 2028. BMS continues to capitalize on Yervoy, which brought in global sales of $2.2bn in 2023. GlobalData is the parent company of Pharmaceutical Technology.

Story continues

"BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

View comments

Bristol Myers Squibb Reports Dip In Net Income For Q2 2024

Bristol Myers Squibb (BMS) has posted a decrease in net income of $1.7bn during the second quarter (Q2) of 2024, a 19% drop compared to $2.1bn for the same period of 2023.

The decline was attributed primarily to higher interest expenses from new debt issued to fund recent acquisitions.

Despite the decline in net income, the company's non-GAAP [generally accepted accounting principles] net earnings rose to $4.2bn, up from $3.7bn in the previous year.

For the three months ended 30 June 2024, revenues also saw an increase, reaching $12.2bn. This is a 9% rise – 11% when adjusted for foreign exchange impacts – from $11.2bn in Q2 2023.

The growth was driven by the company's growth portfolio and the performance of Eliquis.

In the US market, revenues surged by 13% to $8.8bn, attributed mainly to the growth and legacy portfolios.

Access the most comprehensive Company Profiles on the market, View profiles in store Company Profile – free sample

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Submit

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, international revenues experienced a slight decline of 1% to $3.4bn. This was primarily due to a negative 7% impact from foreign exchange and the performance of Revlimid, partly offset by the cancer drug Opdivo.

Earnings per share (EPS) on a GAAP basis fell to 0.83 from 0.99 in the same period of 2023.

The GAAP gross margin also saw a decrease from 74.4% to 73.2%, mainly due to a one-time impairment charge related to marketed product rights.

On a non-GAAP basis, the gross margin showed improvement, increasing from 75.0% to 75.6%, due to a favourable product mix.

The company raised certain 2024 line-item guidance with total revenues now expected in the range of upper end of low single-digits while diluted EPS is expected to be in the range of $0.6 to $0.9.

Bristol Myers Squibb board chair and CEO Christopher Boerner said: "Our second quarter results reflect progress against our strategy to position BMS for long-term, sustainable growth.

"As we move into the second half of the year, we remain focused on prioritising opportunities with the greatest growth potential and impact for patients, including the anticipated US launch of KarXT. We're also driving operational excellence throughout the company, becoming more agile and strengthening execution."

The company announced that the European Medicines Agency (EMA) will begin a review of its application for Opdivo (nivolumab)/Yervoy (ipilimumab) combination's use in patients with advanced liver cancer.

---